





# Profilaxia em infecção de corrente sanguínea

#### **Dra. Beatriz Pascuotte**

Graduação pela Faculdade de Medicina de Ribeirão Preto – FMRP USP

Residência médica em Moléstias Infecciosas pela Faculdade de Medicina de Ribeirão Preto – FMRP USP

Infectologista pelo Grupo de Imunossuprimidos Equipe Dr. João Prats





# Por que pensar em profilaxia?

- Reduzir morbimortalidade
- Diminuir infecções por germes MDR

Boas práticas em neutropenia febril (acessar o risco diariamente)

Estratégias para poupar carbepenemicos

Uso racional de antimicrobianos



# **Estratégias**

Annals of Hematology (2021) 100:2825-2830 https://doi.org/10.1007/s00277-021-04673-y

#### **ORIGINAL ARTICLE**

Early removal of central ve

"Early removal of the CVC had no significant effect on the mortality (OR = 1.16, 95% CI: 0.54-2.47, p = 0.706) in univariate analysis. Furthermore, subsequent bloodstream infection after clinical decision for maintenance or early removal of the CVC was confirmed more frequently in the group with early removal (early removal, 22.6%; the in-hospital mortality ir maintenance, 7.6%, p < 0.0001)"

Tae-Hwan Kim<sup>1</sup> · Yong Won Choi<sup>1</sup> · Mi Sun Ahn<sup>1</sup> · Yoon Seok Choi<sup>1</sup> · Hyun Woo Lee<sup>1</sup> · Seong Hyun Jeong<sup>1</sup> · Seok Yun Kang¹ · Jin-Hyuk Choi¹ · Joon Seong Park¹ · Hyun Young Lee²

Received: 7 June 2021 / Accepted: 15 September 2021 / Published online: 30 September 2021 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Kim TH - Ann Hematol 2021

Coleta de hemoculturas: se há dispositivo, há coleta!





# Impact of central venous catheter reinsertion before and after negative blood culture

## in patients with catheter-related bloodstream infections caused by **Staphylococcus aureus**

Hyeonwoo Kwon<sup>1</sup>, Seongman Bae<sup>1,2\*</sup>, Euijin Chang<sup>1</sup>, Jiwon Jung<sup>1</sup>, Min Jae Kim<sup>1</sup>, Yong Pil Chong<sup>1</sup>, Sung-Han Kim<sup>1</sup>, Sang-Ho Choi<sup>1</sup>, Sang-Oh Lee<sup>1</sup>, Yang Soo Kim<sup>1,2</sup>

<sup>1</sup> Division of Infectious Diseases, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

<sup>2</sup> Center for Antimicrobial Resistance and Microbial Genetics, University of Ulsan College of Medicine, Seoul, Republic of Korea


#### Background

There are insufficient studies evaluating the clinical outcomes based on whether central venous catheter (CVC) reinsertion occurs before or after obtaining negative blood culture results. We assessed the clinical significance of the timing of CVC reinsertion in relation to negative blood culture results in patients with catheter-related bloodstream infections (CRBSIs) caused by Staphylococcus aureus (S. aureus).


#### Methods

In this **retrospective cohort study**, patients with CRBSI caused by *S. aureus* admitted to a tertiary-care hospital in South Korea from **July 2008 through December 2018** were enrolled. The **90-day mortality** and **recurrence of bacteremia** were compared between patients who underwent reinsertion of a central venous catheter before versus after confirmation of negative follow-up blood cultures.

Figure 1. Clinical outcomes of 387 patients with CRBSI caused S. aureus who underwent CVC reinsertion before, after negative blood culture or



# Figure 2. Cumulative Risks of 90-day Mortality. Kaplan-Meier curve analysis, according to timing of CVC reinsertion before or after negative blood culture.



#### Result

Table 1. Clinical outcomes of patients with CRBSI caused by S. aureus

Clinical outcomes	Reinsertion after negative blood culture (n = 95)	Reinsertion before negative blood culture (n = 128)	P val
90-day mortality, n (%)	19 (20.0)	43 (33.6)	0.04
90-day recurrence of bacteremia, n, (%)	4 (4.2)	9 (7.0)	0.55
Bacteremia duration (d), median (IQR)	1 (1-3)	3 (1-7)	<0.0
Metastatic infection, n, (%)	10 (10.5)	34 (26.6)	0.00

Table 2. Results of Cox regression analysis for CVC reinsertion before and after blood culture negativity.

	90-day mortality		90-day recurrence of bacteremia	
	HR (95% CI)	Р	HR (95% CI)	Р
Univariate	1.88 (1.09 - 3.22)	0.02	1.92 (0.59 - 6.25)	0.28
Multivariate*	1.90 (1.02 - 3.52)	0.04	1.44 (0.34 - 6.08)	0.62
IPTW	1.57 (0.85 - 2.90)	0.15	1.44 (0.30 - 6.98)	0.65

#### Conclusions

We found that **reinsertion of a CVC before negative follow-up blood culture results** was significantly associated with **increased 90-day mortality**.

These findings underscore the necessity of confirming negative follow-up cultures before CVC reinsertion in patients with CRBSIs caused by *S. aureus* as per societal guidelines.



# **Estratégias**

- Estudo prospectivo de infecções em pacientes de 9 unidades de hematologia;
- ESBL 23,2% das enterobactérias;
- Uso de profilaxia com quinolona foi associado com aumento do risco de infecções por ESBL (9,7% vs 2,6%).

Ann Hematol (2016) 95:1955–1963 DOI 10.1007/s00277-016-2815-7

#### ORIGINAL ARTICLE

Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel)


```
Chiara Cattaneo<sup>1</sup> · P. Zappasodi<sup>2</sup> · V. Mancini<sup>3</sup> · C. Annaloro<sup>4</sup> · F. Pavesi<sup>5</sup> · C. Skert<sup>6</sup> · A. Ferrario<sup>7</sup> · E. Todisco<sup>8</sup> · V. Saccà<sup>9</sup> · L. Verga<sup>10</sup> · A. Passi<sup>1</sup> · M. Da Vià<sup>2</sup> · S. Ferrari<sup>3</sup> · G. Mometto<sup>4</sup> · M. Petullà<sup>1</sup> · A. Nosari<sup>3</sup> · G. Rossi<sup>1</sup>
```






# Mas...o uso de quinolona é uma estratégia?

Fluoroquinolone resistance rates among community-acquired Enterobacteriaceae isolates in the United States have risen from < 1% to as high as 30% during the decade from the late 1990s to 2009. GI colonization by fluoroquinolone-resistant—and extended-spectrum β-lactamase—positive—gram-negative bacilli has been a risk factor for bacteremic events in the setting of GI mucositis, and fluoroquinolone resistance may result in inappropriate initial empirical antibacterial therapy and increased all-cause mortality. A threshold prevalence of fluoroquinolone resistance among *Escherichia coli* isolates above which the protective efficacy of fluoroquinolone prophylaxis may be limited has not been defined.



The activity of fluoroquinolone prophylaxis on the intestinal microbiome is to select not only for fluoroquinolone-resistant, gram-negative bacilli, but also for *Clostridium difficile* and enterococci. <sup>45</sup> Clinicians must be mindful of the clinical syndromes associated with these pathogens and appropriately tailor their therapeutic approaches.





# Outras estratégias

#### THE BOTTOM LINE (CONTINUED)

(Type: consensus-based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: moderate.)

#### Additional recommended precautions

Recommendation 4.1: All health care workers should comply with hand hygiene and respiratory hygiene/cough etiquette guidelines to reduce the risk for aerosol- and direct or indirect contact—based transmission of pathogenic microorganisms in the health care setting. (Type: consensus-based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: strong.)

Recommendation 4.2: Outpatients with neutropenia from cancer therapy should avoid prolonged contact with environments that have high concentrations of airborne fungal spores (eg, construction and demolition sites, intensive exposure to soil through gardening or digging, or household renovation). (Type: consensus-based; benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: strong.)



### **Considerações finais**

Acessar o risco de neutropenia diariamente



Integridade barreira mucocutânea (cateter e mucosite)



Tipo de imunossupressão



Profilaxia com quinolona: emergência de resistência, efeitos adversos e infecção por Clostridium



**GVHD** 



# Obrigada!

**Dra. Beatriz Pascuotte** 

beatrizpascuotte@gmail.com